Overview

CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors

Status:
Active, not recruiting

Trial end date:
2022-08-14

Target enrollment:

Participant gender:

Summary

This randomized controlled phase II trial will investigate whether the addition of stereotactic body radiotherapy to checkpoint inhibitor treatment in patients with non-small-cell lung carcinoma, urothelial carcinoma, renal cell carcinoma, melanoma or head-and-neck carcinoma can improve progression-free survival as compared to checkpoint inhibitor monotherapy. The primary outcome is progression-free survival; secondary outcomes include overall survival, response according to iRecist and Recist v1.1 and toxicity.

Phase:

Phase 2

Details

Lead Sponsor:

University Hospital, Ghent

Collaborators:

AZ Sint-Lucas
AZ Sint-Lucas Brugge
AZ Sint-Lucas Gent
GZA Ziekenhuizen Campus Sint-Augustinus
Jules Bordet Institute

Treatments:

Atezolizumab
Immune Checkpoint Inhibitors
Nivolumab
Pembrolizumab